Click link below picture
.
Phase II trial demonstrated modest benefit in reducing cognitive decline in patients with Alzheimer’s disease.
An investigational oral drug targeting adrenergic receptors improved scores on memory tests in patients with Alzheimer’s disease in a phase IIa trial, researchers said.
When given with currently approved Alzheimer’s disease drugs, the agent — called ORM-12741 — improved composite memory test scores by 4 percent after 3 months of twice daily treatment, whereas scores worsened by 33 percent in patients receiving memantine and a placebo pill, according to Juha Rouru, MD, of Orion Pharma in Turku, Finland, and colleagues.
.
.
.Click link below for article and video:
http://www.everydayhealth.com/alzheimers/0313/novel-drug-eases-symptoms-in-alzheimers.aspx
.
___________________________________________________
James' World 2 